We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Federal regulators have approved Merck’s acquisition of privately held biotech company Aton Pharma, clearing the way for Merck to re-enter the cancer drug market after a 34-year hiatus.
Antitrust regulators are examining a proposed deal between Barr Laboratories and Galen Holdings that would settle patent litigation and swap marketing rights on several oral contraceptive and hormone-replacement drugs.
The increasing number of so-called “authorized generics” coming to market could attract the attention of federal antitrust regulators, according to pharmaceutical industry experts.
The FTC’s recent ruling that Schering-Plough and several generic firms forged anticompetitive pacts in the 1990s sends a message to drugmakers contemplating similar agreements, though some experts say such deals are no longer in favor in the industry.
Agreements forged in the 1990s between Schering-Plough and two potential generic competitors to settle patent disputes violated antitrust laws by delaying generic competition, according to an FTC ruling last month.